Serum adiponectin levels in adult growth hormone deficiency and acromegaly
Serum adiponectin levels in adult growth hormone deficiency and acromegaly
复制标题
DOI：
10.1016/j.ghir.2004.06.005
复制
发表时间：
2004-12-01
影响因子：
1.4
通讯作者：
Takano, K
中科院分区：
文献类型：
--
作者：
Fukuda, I;Hizuka, N;Takano, K
动脉粥样硬化和胰岛素抵抗是成人生长激素缺乏（GHD）和肢端肥大症的常见并发症。循环脂联素是一种脂肪细胞衍生的蛋白质，具有抗动脉粥样硬化和胰岛素增敏作用。在这项研究中，我们测量了成人 GHD 或肢端肥大症患者的血清脂联素水平，以阐明 GH 分泌状态对血清脂联素水平调节的影响。采用放射免疫法测定了32名成人GHD患者、49名肢端肥大症患者和25名正常人的血清脂联素水平。然后研究脂联素与胰岛素敏感性指标（定量胰岛素敏感性检查指数（QUICKI）、BMI、血清 GH 和 IGF-I 水平之间的关系）。与正常受试者相比，肢端肥大症或成人 GHD 患者的 QUICKI 值显着较低（分别为 0.33 +/- 0.03、P < 0.01、0.35 +/- 0.04、P < 0.05 和 0.36 +/- 0.01）。虽然成人 GHD 患者的血清脂联素水平显着低于肢端肥大症患者 (6.5 +/- 3.9, 9.2 +/- 5.0, P < 0.01)，但这些水平与正常受试者中发现的水平 (7.8 +/- 4.3 mug/ml) 没有显着差异。两组患者血清脂联素水平与BMI均呈负相关（GHD r = -0.39，P < 0.05；肢端肥大症r = -0.35，P < 0.05）。然而，仅在成人 GHD 患者中，血清脂联素水平与 QUICKI 呈正相关（R-s = 0.37，P < 0.05）。在肢端肥大症患者中，循环脂联素水平与血清 IGF-I 水平呈负相关（R-s = -0.34，P < 0.05），但与基础 GH 水平无关。这些结果表明，成人 GHD 患者的脂联素水平显着低于肢端肥大症患者。 GHD 患者和健康对照者的脂联素水平相似，而肢端肥大症患者的脂联素水平与 BM1 相比似乎并不密切相关。在成人 GHD 和肢端肥大症组中观察到的脂联素和 QUICKI 之间的不同关系可能反映了 GH 缺乏或过量状态下胰岛素抵抗机制的差异。 (C) 2004 Elsevier Ltd. 保留所有权利。
Atherosclerosis and insulin resistance are common complications of adult growth hormone deficiency (GHD) and acromegaly. Circulating adiponectin, an adipocyte-derived protein, has both anti-atherogenic and insulin-sensitising effects. In this study, we measured serum adiponectin levels in patients with either adult GHD or acromegaly to clarify the impact of GH secretory states on the regulation of serum adiponectin levels. Serum adiponectin level was measured by radioimmunoassay in 32 patients with adult GHD, 49 patients with acromegaly and 25 normal subjects. The relationships between adiponectin and insulin sensitivity index assessed as quantitative insulin sensitivity check index (QUICKI), BMI, and serum GH and IGF-I levels were then investigated. The values of QUICKI were significantly lower in patients with acromegaly or adult GHD compared to normal subjects (0.33 +/- 0.03, P < 0.01, 0.35 +/- 0.04, P < 0.05 and 0.36 +/- 0.01, respectively). While patients with adult GHD had significantly lower serum adiponectin levels than patients with acromegaly (6.5 +/- 3.9, 9.2 +/- 5.0, P < 0.01) these levels were not significantly different from those found in normal subjects (7.8 +/- 4.3 mug/ml). There was an inverse correlation between serum adiponectin levels and BMI in both patient groups (GHD r = -0.39, P < 0.05; Acromegaly r = -0.35, P < 0.05). However, serum adiponectin levels correlated positively with QUICKI (R-s = 0.37, P < 0.05) only in patients with adult GHD. In patients with acromegaly, the levels of circulating adiponectin showed, an inverse correlation with serum IGF-I levels (R-s = -0.34, P < 0.05), but not with basal GH levels. These results demonstrate that adiponectin levels are significantly lower in patients with adult GHD than in patients with acromegaly. Adiponectin levels are similar in patients with GHD and healthy controls, whereas in patients with acromegaly, insulin resistance appears to be not closely related to adiponectin levels compared with BM1. The different relationship between adiponectin and QUICKI observed in the adult GHD and acromegaly groups presumably reflects differences in the mechanisms of insulin resistance under states of GH deficiency or excess. (C) 2004 Elsevier Ltd. All rights reserved.